Melvin LK CHUA | FRCR, PhD, FASCO
@DrMLChua
Followers
2K
Following
8K
Media
319
Statuses
2K
Chair, HN&Thorax Cancers | Clinician-Scientist @NCCS | FASCO @ASCO | Clinical Trials Chair @HNCIG | Commissioner @ICRU_org | Trustee @Alicesarc
Singapore
Joined February 2017
Finally came in the post! . The go-to “Devita” txtbk everyone uses for their Boards & residencies for ready info updated & reformatted to suit the rapidly changing field of Oncology. Glad to have contributed to the #Nasopharynxcancer chapter & see familiar names @DrSpratticus
4
10
80
Always fun to spend a productive morning sharing on #ProtonBeam in cancers particularly #HeadNeckCancer with the Singapore Cancer Society community of #patients and #survivors.Equally impactful as giving academic talks!.It is humbling to have patient sharing their experiences!
1
0
13
We know that TILs are abundant in #NasopharyngealCarcinoma . While it is certainly more complex than quantity, previous work indicated that %TILs may be prognostic in NPC. We took the FIRST step using #DeepLearning to read H+E slides. More to come! .
3
5
18
RT @_ShankarSiva: 🥳 Today, we randomised the final patient on @TROGfightcancer 19.06 DECREASE trial! This trial randomised patients with….
0
34
0
I hope to see you at the @ASTRO_org 2025 Annual Meeting Sep 27 to Oct 1. You will not want to miss this novel educational session led by @drdavidpalma on emerging indications for RT in polymetastatic cancers. It is timely and on point for the AM theme.
1
0
6
RT @SameerKeoleMD: I hope to see you at the @ASTRO_org 2025 Annual Meeting Sep 27 to Oct 1. You will not want to miss this novel education….
amportal.astro.org
0
8
0
Welcome back @drdavidpalma !.
I decided to rejoin X because there just isn't the same #radonc community on the other platforms. Over the next couple of days, I'll post some updates on some research and the ARC Bootcamp. Thanks @_ShankarSiva for the nudge to come back!.
0
0
2
RT @drdavidpalma: I decided to rejoin X because there just isn't the same #radonc community on the other platforms. Over the next couple o….
0
9
0
What a #Legend He was one of the few who always kept it FUN and REAL and left a lasting impression when I first heard him speak at @ASTRO_org Annual Meeting . @a_dalpra @aleberlin2 @DrSpratticus @VedangMurthy @seanmmcbride @drkevin_chua_lm @mikemejiamd @_ShankarSiva.
📢Special day: Literally Dr. Anthony Zietman's Last Day in #radonc clinic😳🥳😔. After 3️⃣9️⃣ years of service🙏🙏🙏. Handing the torch 🔥(for the clinic space that is😉) to @sophia_kamran 😅. A loss for our field, but he is going out on top‼️⛰️. @sueyom
3
4
25
What a great summary on treatment of #Oligometastatic #ProstateCancer ! Congrats @VedangMurthy @drmaneesh_singh @piet_ost . Good learning for every Resident and Senior Faculty! 💪🏻💪🏻
Thrilled and Grateful. Our review on metastasis-directed therapy in oligometastatic prostate cancer is now out in Seminars in Radiation Oncology. Thank you so much @VedangMurthy @piet_ost for your guidance and belief! .Full text
1
13
36
RT @drmaneesh_singh: Thrilled and Grateful. Our review on metastasis-directed therapy in oligometastatic prostate cancer is now out in Semi….
0
16
0
Interesting poll from #NasopharyngealCarcinoma. Meeting in Guangzhou among Chinese Experte. What should be the SOC for high-risk NPC trial? @imrtlee @Qle_stanford @sueyom @mikemejiamd @lachiemcd @Larvol @oncodaily . In case translation is needed, option 1 is IC+CRT and option 2
2
2
13
Always nice to visit Guangzhou for another #NasopharyngealCarcinoma. #ProtonTherapy meeting to discuss practice in the real world. OS rates may be improving >70%, BUT still lots of patients with bad disease and early relapse so lots more to do! . Thanks to Prof Mai for the
0
3
20
#ASCO2025. #PresidentReception . Learning something from the 🤴 of #selfies @PGrivasMDPhD @drkevin_chua_lm . Such a great gathering of people and I can’t help but promote #ASCOBT2026 #ASCOBreakthrough when you have Singapore sling as a cocktail drink!
0
1
18
The field of #HeadNeckCancer just got more interesting! . #ASCO2025 .#Plenary . NIVO-POSTOP study was an important IIS for high risk HNSCC.Positive DFS @ 3y.But signal is primarily locoregional control! .Stark contrast to KN689. Kudos to GORTEC @PBlanchardMD .Thoughts??
4
22
55
Several promising targets in #HeadNeckCancer . BCA101 targeting HPV- population looks exciting and glad to be involved in the steering committee of FORTFI-HN01 . The deep responses esp for the CPS1-19 subset are exciting! Much to learn about the #HeadNeckBiology . @KaramLab
1
3
20